Single Versus Double Antiplatelet Therapy in Patients Undergoing Endovascular Treatment With a Stent for an Iliac Occlusive Lesion

Abstract

Objective

Endovascular treatment (EVT) for an aorto-iliac occlusive lesion is performed worldwide as first-line treatment. However, the choice of single antiplatelet therapy (SAPT) or double antiplatelet therapy (DAPT) after aorto-iliac revascularization is controversial. The purpose of the study was to assess clinical outcomes in patients with SAPT or DAPT after iliac EVT, using propensity score matching.

Method

Patients who underwent EVT for a de-novo iliac occlusive lesion at a single center from 2017 to 2023 were analyzed retrospectively. Comparisons were made between SAPT and DAPT cases after propensity score matching. The primary endpoints of the study were freedom from restenosis and freedom from target lesion revascularization (TLR).

Results

A total of 150 patients underwent iliac EVT and received SAPT (n = 93) or DAPT (n = 57). The DAPT group had a significantly higher rate of coronary artery disease (P = .010). After matching, the differences in baseline and procedural details were diminished. The technical success rate of EVT, access site complications, and manual compression time did not differ between the groups. The median follow-up period was 33 (20-47) months. During follow-up, restenosis occurred in 11 cases (7%) and 10 cases (7%) underwent TLR. After matching, the 5-year freedom from restenosis did not differ significantly in the SAPT and DAPT groups (92% vs 90%, P = .80). Freedom from TLR also did not differ between the groups (P = .80). There was a tendency for a lower incident rate of major bleeding in the SAPT group (7% vs 18% at 5 years, P = .10).

Conclusions

Retrospective analysis using propensity score matching showed that SAPT after iliac EVT resulted in similar freedom from restenosis and TLR compared with DAPT.

Keywords

iliac occlusive lesion endovascular treatment restenosis antiplatelet therapy major bleeding events

Get full access to this article

View all access options for this article.

References

Aboyans

Ricco

Bartelink

MEL

, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European stroke organization (ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095

Gerhard-Herman

Gornik

Barrett

, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):e71-e126. doi:10.1016/j.jacc.2016.11.007

Conte

Bradbury

Kolh

, et al. Global vascular guideline on management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1-109. doi:10.1016/j.ejvs.2019.05.006

CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339. doi:10.1016/s0140-6736(96)09457-3

Bhatt

Fox

Hacke

, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717. doi:10.1056/NEJMoa060989

Cassar

Ford

Greaves

Bachoo

Brittenden

. Randomized clinical trial of the antiplatelet effects of aspirinclopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg. 2005;92(2):159-165. doi:10.1002/bjs.4810

Steinhubl

Berger

Mann

, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411-2420. doi:10.1001/jama.288.19.2411

Cassar

Ford

Greaves

Bachoo

Brittenden

. Randomized clinical trial of the antiplatelet effects of aspirinclopidogrel combination versus aspirin alone after lower limb angioplasty. Br J Surg. 2005;92(2):159-165. doi:10.1002/bjs.4810

Tepe

Bantleon

Brechtel

, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapydthe MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012;22(9):1998-2006. doi:10.1007/s00330-012-2441-2

10.

Katsanos

Spiliopoulos

Saha

, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One. 2015;10(8):e0135692. doi:10.1371/journal.pone.0135692

11.

Mehran

Rao

Bhatt

, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747. doi:10.1161/CIRCULATIONAHA.110.009449

12.

Schulman

Kearon

. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. doi:10.1111/j.1538-7836.2005.01204.x

13.

Norgren

Hiatt

Dormandy

Nehler

Harris

Fowkes

FGR

TASC II Working Group . Inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ). J Vasc Surg. 2007;45(Suppl S):S5-S67. doi:10.1016/j.jvs.2006.12.037

14.

Kanda

. Investigation of the freely-available easy-to-use software EZR for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458. doi:10.1038/bmt.2012.244

15.

Strobl

Brechtel

Schmehl

, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther. 2013;20(5):699-706. doi:10.1583/13-4275MR.1

16.

Iida

Takahara

Yamauchi

, et al. Impact of hospital volume on clinical outcomes after aortoiliac stenting in patients with peripheral artery disease. J Atheroscler Thromb. 2020;27(6):516-523. doi:10.5551/jat.51631

17.

Nguyen

Diodati

Pharand

. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-1164. doi:10.1016/j.jacc.2005.01.034

18.

Belch

Dormandy

CASPAR Writing Committee Biasi

Cairols

Diehm

Eikelboom

. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825-833. doi:10.1016/j.jvs.2010.04.027. e1-e2.